The human body is becoming the latest frontier of corporate enclosure as pharmaceutical titans Eli Lilly and Novo Nordisk solidify a 'metabolic divide' through subscription-based healthcare. With the FDA approval of Lilly’s oral GLP-1 orforglipron, the market for obesity and diabetes management has transitioned into a recurring revenue model that mimics enterprise software. While generic versions of semaglutide are launching for $15 in the Global South, Western patients are being corralled into high-cost, monthly 'health management' plans. This is the commodification of the human biological baseline. Simultaneously, the approval of implantable brain-computer interfaces (BCIs) for commercial use in China and the rise of medtech startups like Epia Neuro suggest a future where even our neural pathways are subject to 'read/write' monetization. These 'living pharmacies' and BCIs are not merely medical advancements; they are the initial hardware of a tiered biological class system. Those who can afford the subscription will enjoy optimized metabolic and cognitive health, while the rest are left to navigate a collapsing public health infrastructure. This is the ultimate expression of capital's logic: it no longer seeks to merely sell us a cure, it seeks to lease us our own physiological functionality. We are entering an era where being 'human' at a baseline level of health is a service-level agreement that can be revoked if the payment fails.